Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 3/20 | 0.41 |
| ▸ | TNKS | O95271 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14678673 | 0.90 | MMP2 (0.82) | MMP2ESR1ESR2XDHTNKS | |
| Obovator SCHEMBL33525039 | 0.81 | MMP2 (0.67) | MMP2ESR1ESR2XDHTNKS | |
| Obovator SCHEMBL454929 | 0.81 | MMP2 (0.67) | MMP2ESR1ESR2XDHTNKS | |
| SCHEMBL565507 | 0.73 | MMP2 (0.55) | MMP2ESR1ESR2XDHALDH1A1 | |
| SCHEMBL565508 | 0.73 | MMP2 (0.55) | MMP2ESR1ESR2XDHALDH1A1 | |
| Isomagnolol SCHEMBL30069180 | 0.72 | ALDH1A1 (0.66) | MMP2XDHTNKSPARP1ALDH1A1 | |
| SCHEMBL18838060 | 0.70 | TNKS (0.61) | MMP2ESR1ESR2TNKSALDH1A1 | |
| SCHEMBL30114989 | 0.70 | TNKS (0.69) | MMP2ESR1ESR2XDHTNKS | |
| SCHEMBL31046737 | 0.69 | GABRA1 (0.66) | MMP2ESR1ESR2XDHTNKS | |
| SCHEMBL30284517 | 0.69 | GABRA1 (0.66) | MMP2ESR1ESR2XDHTNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367736-B2 | Anticancer composition comprising obovatol or obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-02-05 | — | — | US | claimed |
| US-20080312337-A1 | Anticancer Composition Comprising Obovatol or Obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-12-18 | — | — | US | claimed |
| US-20070037889-A1 | Anticancer composition comprising obovatol or obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-02-15 | — | — | US | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4593859-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | Eresina, LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024073013-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA, LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073011-A1 | TOPICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA, LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| US-8367736-B2 | Anticancer composition comprising obovatol or obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-02-05 | — | — | US | disclosed |
| US-8367736-B2 | Anticancer composition comprising obovatol or obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-02-05 | — | — | US | disclosed |
| US-8367736-B2 | Anticancer composition comprising obovatol or obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-02-05 | — | — | US | disclosed |
| US-8367736-B2 | Anticancer composition comprising obovatol or obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-02-05 | — | — | US | disclosed |
| US-20080312337-A1 | Anticancer Composition Comprising Obovatol or Obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-12-18 | — | — | US | disclosed |
| US-20080312337-A1 | Anticancer Composition Comprising Obovatol or Obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-12-18 | — | — | US | disclosed |
| US-20080312337-A1 | Anticancer Composition Comprising Obovatol or Obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-12-18 | — | — | US | disclosed |
| US-20080312337-A1 | Anticancer Composition Comprising Obovatol or Obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-12-18 | — | — | US | disclosed |
| US-20070037889-A1 | Anticancer composition comprising obovatol or obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-02-15 | — | — | US | disclosed |
| US-20070037889-A1 | Anticancer composition comprising obovatol or obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-02-15 | — | — | US | disclosed |
| US-20070037889-A1 | Anticancer composition comprising obovatol or obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-02-15 | — | — | US | disclosed |
| US-20070037889-A1 | Anticancer composition comprising obovatol or obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-02-15 | — | — | US | disclosed |
| US-20070037889-A1 | Anticancer composition comprising obovatol or obovatal | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312337-A1 | Anticancer Composition Comprising Obovatol or Obovatal | MMP2, MMP9, MMP7 | MMP2 1/4885ESR1 3629/4885ESR2 1834/4885 |
| US-20070037889-A1 | Anticancer composition comprising obovatol or obovatal | MMP2, MMP9, MMP7 | MMP2 1/4885ESR1 3629/4885ESR2 1834/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | MMP2 392/4885ESR1 3665/4885ESR2 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.